Invention Grant
- Patent Title: Variants of humanized anti-carcinoma MAb CC49
- Patent Title (中): 人源化抗癌MAb CC49的变体
-
Application No.: US12819920Application Date: 2010-06-21
-
Publication No.: US08029788B2Publication Date: 2011-10-04
- Inventor: Syed V S Kashmiri , Eduardo A. Padlan , Jeffrey Schlom
- Applicant: Syed V S Kashmiri , Eduardo A. Padlan , Jeffrey Schlom
- Applicant Address: US DC Washington
- Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
- Current Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
- Current Assignee Address: US DC Washington
- Agency: Klarquist Sparkman, LLP
- Main IPC: A61K39/395
- IPC: A61K39/395 ; A61K39/00
Abstract:
The invention is directed towards mouse-human chimeric variants of CC49 monoclonal antibodies with minimal murine content. A first aspect of the invention provides CDR variants of humanized monoclonal antibody (HuCC49) in which less than all six (three heavy chain and three light chain) Complementarity Determining Regions (CDRs) of CC49 are present. A second aspect of the invention provides SDR variants of humanized monoclonal antibody (HuCC49) in which only Specificity Determining Regions (SDRs) of at least one CDR from CC49 are present. The invention is also directed towards biotechnological methods of making the variants and therapeutic methods of using the variants.
Public/Granted literature
- US20100303720A1 VARIANTS OF HUMANIZED ANTI-CARCINOMA MAb CC49 Public/Granted day:2010-12-02
Information query
